These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2701727)

  • 41. DNA-flow cytometry studies in blood and marrow cells from chronic myelogenous leukemia patients treated with interferon alpha-2b.
    Wandl UB; May D; Peltzer T; Kloke O; Opalka B; Niederle N; Streffer C
    Leuk Res; 1990; 14(10):905-8. PubMed ID: 2259227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of chronic myelogenous leukemia with interferons alpha and gamma.
    Kloke O; May D; Wandl U; Becher R; Opalka B; Beer U; Niederle N
    Blut; 1990 Jul; 61(1):45-6. PubMed ID: 2117476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia.
    Opalka B; Kloke O; Bartram CR; Beer U; Janssen JW; Niederle N; Wandl UB
    Lancet; 1989 Jun; 1(8650):1334. PubMed ID: 2566865
    [No Abstract]   [Full Text] [Related]  

  • 44. The current status of interferon alpha in haemic malignancy.
    Galvani DW; Cawley JC
    Blood Rev; 1990 Sep; 4(3):175-80. PubMed ID: 2245253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-alpha treatment.
    Clauss IM; Vandenplas B; Wathelet MG; Dorval C; Delforge A; Content J; Stryckmans P; Huez GA
    Blood; 1990 Dec; 76(11):2337-42. PubMed ID: 1701667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon alpha.
    Pawelec G; Reutter M; Owsianowsky M; Rehbein A; Busch FW
    Cancer Immunol Immunother; 1991; 33(1):54-60. PubMed ID: 1902397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferons for the treatment of hematological malignancies.
    Urabe A
    Oncology; 1994; 51(2):137-41. PubMed ID: 7515169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liver failure due to recombinant alpha interferon for chronic myelogenous leukaemia.
    Wandl UB; Kloke O; Niederle N
    Lancet; 1992 Jan; 339(8785):123-4. PubMed ID: 1345846
    [No Abstract]   [Full Text] [Related]  

  • 49. Interferon-induced vasospasm in chronic myeloid leukaemia.
    Zeidman A; Dicker D; Mittelman M
    Acta Haematol; 1998; 100(2):94-6. PubMed ID: 9792941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-interferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia.
    Aitchison R; Allen P; Schey S; Newland AC
    Br J Haematol; 1991 Jul; 78(3):465-7. PubMed ID: 1873235
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapy with recombinant interferon alpha-2c during unexpected pregnancy in a patient with chronic myeloid leukaemia.
    Reichel RP; Linkesch W; Schetitska D
    Br J Haematol; 1992 Oct; 82(2):472-3. PubMed ID: 1419831
    [No Abstract]   [Full Text] [Related]  

  • 52. Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia.
    Kloke O; Becher R; Niederle N
    Blut; 1987 Nov; 55(5):453-8. PubMed ID: 3118992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic myelogenous leukaemia: haematological remissions with alpha interferon.
    Talpaz M; McCredie K; Kantarjian H; Trujillo J; Keating M; Gutterman J
    Br J Haematol; 1986 Sep; 64(1):87-95. PubMed ID: 3463363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The beneficial effects of alpha IFN in CGL are probably not mediated by NK cells.
    Galvani DW; Owens W; Nethersell AB; Cawley JC
    Br J Haematol; 1989 Feb; 71(2):233-7. PubMed ID: 2923809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon in the treatment of chronic myeloid leukemia. Proceedings of a workshop. February 4-7, 1993, Flims, Switzerland.
    Semin Hematol; 1993 Jul; 30(3 Suppl 3):1-54. PubMed ID: 8235695
    [No Abstract]   [Full Text] [Related]  

  • 56. Hypothyroidism and arthritis during interferon therapy.
    D'Hondt L; Delannoy A; Docquier C
    Clin Rheumatol; 1993 Sep; 12(3):415-7. PubMed ID: 7504985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting responses to interferon.
    Lancet; 1990 Dec; 336(8727):1388-9. PubMed ID: 1978206
    [No Abstract]   [Full Text] [Related]  

  • 58. Interferon-alpha in childhood haematological malignancies.
    Simkó R; Nagy K
    Postgrad Med J; 1996 Dec; 72(854):709-13. PubMed ID: 9015462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytotoxic effect of interferon on primary malignant tumour cells. Studies in various malignancies.
    Grandér D; Xu B; Einhorn S
    Eur J Cancer; 1993; 29A(14):1940-3. PubMed ID: 7506559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The activity of alpha interferons in chronic myelogenous leukemia.
    Talpaz M
    Am J Med Sci; 1988 Aug; 296(2):95-7. PubMed ID: 3165249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.